Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 8, 2026

All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy

Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Jun 8, 2026

SRPT vs. ARGX: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Sarepta Therapeutics (SRPT) or argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Jun 8, 2026

Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 5, 2026

Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript

Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript

Seeking Alpha • Jun 4, 2026

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40 a.m. ET at the Loews Miami Beach Hotel in Miami Beach, Fla. Oppenheimer CNS and Neuro-Muscular Summit Investor meetings: Wednesday, June 10, 2026 at The Bath Club i.

Business Wire • Jun 1, 2026

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference at the InterContinental New York Barclay on Wednesday, May 20, at 8:30 a.m. ET. The presentations will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presen.

Business Wire • May 13, 2026

Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?

Sarepta stock toppled Thursday as investors digested the better-than-feared sales of its beleaguered gene therapy, Elevidys.

Investors Business Daily • May 7, 2026

Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained

SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.

Zacks Investment Research • May 7, 2026

Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript

Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026